Martin Shkreli faces another lawsuit, this time from insurer, alleging plans to create a monopoly for Daraprim

The notorious “Pharma Bro” Martin Shkreli prompted national outrage in 2015 when he and then-Turing Pharmaceuticals raised the price of Daraprim, the “gold standard” treatment of the parasitic infection toxoplasmosis, from $17.50 to $750 per tablet. Despite this, he was ultimately jailed in 2017 for unrelated securities fraud charges for misleading investors in one of his other companies, Retrophin.